Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Ann Surg. 2023 Apr 1;277(4):e864-e871. doi: 10.1097/SLA.0000000000005160. Epub 2021 Aug 19.
This study aimed to perform a multicenter comparison between robotic pancreaticoduodenectomy (RPD) and open pancreaticoduodenectomy (OPD).
Previous comparisons of RPD versus OPD have only been carried out in small, single-center studies of variable quality.
Consecutive patients who underwent RPD (n = 1032) or OPD (n = 1154) at 7 centers in China between July 2012 and July 2020 were included. A 1:1 propensity score matching (PSM) was performed.
After PSM, 982 patients in each group were enrolled. The RPD group had significantly lower estimated blood loss (EBL) (190.0 vs 260.0 mL; P < 0.001), and a shorter postoperative 1length of hospital stay (LOS) (12.0 (9.0-16.0) days vs 14.5 (11.0-19.0) days; P < 0.001) than the OPD group. There were no significant differences in operative time, major morbidity including clinically relevant postoperative pancreatic fistula (CR-POPF), bile leakage, delayed gastric emptying, postoperative pancreatectomy hemorrhage (PPH), reoperation, readmission or 90-day mortality rates. Multivariable analysis showed R0 resection, CR-POPF, PPH and reoperation to be independent risk factors for 90-day mortality. Subgroup analysis on patients with pancreatic ductal adenocarcinoma (PDAC) (n = 326 in each subgroup) showed RPD had advantages over OPD in EBL and postoperative LOS. There were no significant differences in median disease-free survival (15.2 vs 14.3 months, P = 0.94) or median overall survival (24.2 vs 24.1 months, P = 0.88) between the 2 subgroups.
RPD was comparable to OPD in feasibility and safety. For patients with PDAC, RPD resulted in similar oncologic and survival outcomes as OPD.
本研究旨在对机器人胰十二指肠切除术(RPD)与开腹胰十二指肠切除术(OPD)进行多中心比较。
之前的 RPD 与 OPD 比较仅在质量不同的小范围、单中心研究中进行过。
纳入 2012 年 7 月至 2020 年 7 月在中国 7 家中心接受 RPD(n=1032)或 OPD(n=1154)的连续患者。进行了 1:1 倾向评分匹配(PSM)。
PSM 后,每组纳入 982 例患者。RPD 组的估计出血量(EBL)明显较低(190.0 与 260.0 mL;P<0.001),术后住院时间(LOS)较短(12.0(9.0-16.0)天与 14.5(11.0-19.0)天;P<0.001)。手术时间、主要发病率(包括临床相关胰瘘(CR-POPF)、胆漏、胃排空延迟、术后胰腺出血(PPH)、再次手术、再入院或 90 天死亡率)无显著差异。多变量分析显示,RO 切除、CR-POPF、PPH 和再次手术是 90 天死亡率的独立危险因素。在胰腺导管腺癌(PDAC)患者亚组(每组 n=326)中,RPD 在 EBL 和术后 LOS 方面优于 OPD。两组之间无中位无病生存期(15.2 与 14.3 个月,P=0.94)或中位总生存期(24.2 与 24.1 个月,P=0.88)的显著差异。
RPD 在可行性和安全性方面与 OPD 相当。对于 PDAC 患者,RPD 的肿瘤学和生存结果与 OPD 相似。